Dingxin Wang1, 2, Ron Gaba3, Brian Jin4, Robert Lewandowski4, 5, Robert Ryu4, Kent Sato4, Laura Kulik6, Mary Mulcahy7, 8, Andrew Larson4, 5, Riad Salem4, 5, Reed Omary4, 5
1Siemens Medical Solutions USA, Inc., Minneapolis, MN, United States; 2Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, United States; 3Department of Radiology, University of Illinois at Chicago, Chicago, IL, United States; 4Department of Radiology, Northwestern University, Chicago, IL, United States; 5Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States; 6Department of Hepatology, Northwestern University, Chicago, IL, United States; 7Department of Medicine, Northwestern University, Chicago, IL, United States; 8Robert H. Lurie Comprehensive Cancer Center,, Northwestern University, Chicago, IL, United States
In this study, we tested the hypothesis that TRIP-MRI monitored tumor perfusion changes during TACE can predict overall survival in patients with unresectable HCC. Our study shows the evidence of association between intra-procedural tumor perfusion reduction during TACE and overall survival. TACE provided better survival benefit when relative perfusion reduction was 35-85%. The present results also suggest that TRIP-MRI performed within an integrated MR-DSA unit may serve as an intra-procedural imaging biomarker to predict survival in patients with unresectable HCC at the time of TACE procedure.
Keywords